Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.

Quoin Pharmaceuticals, Ltd.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

 RECEIVES FDA CONDITIONAL APPROVAL OF QYLEKI AS THE PROPOSED BRAND NAME FOR QRX003 FOR NETHERTON SYNDROME  REPORTS POSITIVE CLINICAL UPDATE FROM ONGOING PEDIATRIC COMPASSIONATE USE PROGRAM IN NETHERTON SYNDROME  RECEIVES U.S. NOTICE OF ALLOWANCE FOR A PATENT COVERING A COMBINATION TREATMENT FOR NETHERTON SYNDROME  SUBMITS FIRST-EVER IND FOR PEELING SKIN SYNDROME; FDA CLEARANCE RECEIVED SUBSEQUENT TO QUARTER END, ENABLING FIRST COMPANY-SPONSORED PHASE 2/3 STUDY TO INITIATE IN 2H 2026  ADVANCES QRX009 TOPICAL RAPAMYCIN PLATFORM TOWARD CLINICAL TESTING IN A NUMBER OF INDICATIONS ASHBURN, VA., AUG. 14, 2026 (GLOBE NEWSWIRE) -- QUOIN PHARMACEUTICALS LTD.

QUOIN PHARMACEUTICALS PROVIDES CORPORATE UPDATE AND REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

ASHBURN, VA., AUG. 07, 2026 (GLOBE NEWSWIRE) -- QUOIN PHARMACEUTICALS LTD. (NASDAQ: QNRX) (THE "COMPANY" OR "QUOIN"), A LATE CLINICAL-STAGE SPECIALTY PHARMACEUTICAL COMPANY FOCUSED ON RARE AND ORPHAN DISEASES, TODAY ANNOUNCED THAT IT PLANS TO PROVIDE A CORPORATE UPDATE AND RELEASE ITS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2026, BEFORE THE MARKET OPENS ON FRIDAY, AUGUST 14, 2026.

QUOIN PHARMACEUTICALS TO ANNOUNCE CORPORATE UPDATE AND SECOND QUARTER 2026 FINANCIAL RESULTS ON FRIDAY, AUGUST 14, 2026

QUOIN PHARMACEUTICALS (NASDAQ: QNRX) RECEIVES FDA IND CLEARANCE FOR A PHASE 2 STUDY OF QRX003 IN PEELING SKIN SYNDROME, WITH INITIATION EXPECTED IN 2H 2026

QUOIN PHARMACEUTICALS RECEIVES FDA IND CLEARANCE TO INITIATE PHASE 2 STUDY OF QRX003 IN PEELING SKIN SYNDROME

ASHBURN, VA., JUNE 30, 2026 (GLOBE NEWSWIRE) -- QUOIN PHARMACEUTICALS LTD.

QUOIN PHARMACEUTICALS RECEIVES U.S. NOTICE OF ALLOWANCE FOR PATENT COVERING COMBINATION TREATMENT FOR NETHERTON SYNDROME

QRX003 HOLDS ORPHAN DRUG DESIGNATION IN THE UNITED STATES, THE EUROPEAN UNION, AND JAPAN, PLUS FAST TRACK AND RARE PEDIATRIC DISEASE DESIGNATIONS FROM THE FDA PIVOTAL PHASE 3 STUDY EXPECTED TO INITIATE IN THE SECOND HALF OF 2026, WITH POTENTIAL NDA FILING IN 2027 POSITIVE CLINICAL UPDATE FROM ONGOING PEDIATRIC COMPASSIONATE USE PROGRAM RELEASED ON JUNE 16 QRX003 REMAINS ON TRACK TO POTENTIALLY BECOME THE FIRST APPROVED TREATMENT FOR NETHERTON SYNDROME ASHBURN, VA., JUNE 23, 2026 (GLOBE NEWSWIRE) -- QUOIN PHARMACEUTICALS LTD.

QUOIN PHARMACEUTICALS RECEIVES FDA CONDITIONAL APPROVAL OF QYLEKI AS THE PROPOSED BRAND NAME FOR QRX003 FOR NETHERTON SYNDROME

SUPPORTS QUOIN'S PLANNED DIRECT COMMERCIALIZATION OF QRX003 IN JAPAN, ONE OF ITS THREE CORE COMMERCIAL TERRITORIES FOLLOWS RECENT GRANT OF ORPHAN DRUG DESIGNATION TO QRX003 BY JAPAN'S MHLW ASHBURN, VA., JUNE 18, 2026 (GLOBE NEWSWIRE) -- QUOIN PHARMACEUTICALS LTD.

QUOIN PHARMACEUTICALS COMPLETES ESTABLISHMENT OF JAPANESE SUBSIDIARY TO ADVANCE COMMERCIAL READINESS FOR QRX003

FOUR OF SIX PATIENTS PARTICIPATING IN THE COMPASSIONATE USE PROGRAM WERE CLASSIFIED ASIMPROVED' OR SIGNIFICANTLY IMPROVED' FROM BASELINE ASSESSMENT ACROSS KEY CLINICAL ENDPOINTS ALL SIX PATIENTS ARE YOUNGER THAN 10 YEARS OF AGE, WITH THE YOUNGEST BEING JUST 6 MONTHS OLD DURATION OF TREATMENT TO-DATE RANGES FROM 3 WEEKS TO 15 MONTHS NO TREATMENT RELATED ADVERSE EVENTS REPORTED FOR ALL SIX PATIENTS ADDITIONAL PEDIATRIC PATIENTS ENROLLING IN PROGRAM IN JUNE AND SEPTEMBER QUOIN PLANS A COMPREHENSIVE DATA RELEASE, INCLUDING FROM ONGOING PHASE 2 STUDIES, IN THE COMING MONTHS ASHBURN, VA., JUNE 16, 2026 (GLOBE NEWSWIRE) -- QUOIN PHARMACEUTICALS LTD.

QUOIN PHARMACEUTICALS ANNOUNCES POSITIVE CLINICAL UPDATE FROM ONGOING PEDIATRIC NETHERTON SYNDROME COMPASSIONATE USE PROGRAM

-DESIGNATION PROVIDES REGULATORY AND DEVELOPMENT INCENTIVES IN JAPAN, INCLUDING UP TO 10 YEARS OF MARKET EXCLUSIVITY UPON APPROVAL- -FOLLOWS ORPHAN DRUG DESIGNATION, PEDIATRIC RARE DISEASE DESIGNATION, AND FAST TRACK DESIGNATION PREVIOUSLY GRANTED BY THE U.S. FDA, AND ORPHAN DRUG DESIGNATION PREVIOUSLY GRANTED BY THE EUROPEAN MEDICINES AGENCY- -QUOIN IS WORKING CLOSELY WITH LEADING JAPANESE CLINICIANS TO REFINE CLINICAL AND REGULATORY PATHWAY FOR APPROVAL- ASHBURN, VA., JUNE 04, 2026 (GLOBE NEWSWIRE) -- QUOIN PHARMACEUTICALS LTD.

QUOIN PHARMACEUTICALS ANNOUNCES JAPAN'S MHLW GRANTS ORPHAN DRUG DESIGNATION FOR QRX003 IN NETHERTON SYNDROME

-FIRST EVER IND SUBMISSION FOR THIS DISEASE, WHICH HAS NO CURRENT TREATMENT OR CURE- -QUOIN PLANS PHASE 2 STUDY INITIATION IN 2H 2026- -SUBMISSION SUPPORTED BY POSITIVE INITIAL CLINICAL DATA FROM INVESTIGATOR-LED PEDIATRIC STUDY- -SECOND INDICATION FOR QRX003, IN ADDITION TO NETHERTON SYNDROME- ASHBURN, VA., JUNE 02, 2026 (GLOBE NEWSWIRE) -- QUOIN PHARMACEUTICALS LTD.

QUOIN PHARMACEUTICALS SUBMITS IND APPLICATION FOR QRX003 IN PEELING SKIN SYNDROME

 FILED BREAKTHROUGH MEDICINE DESIGNATION APPLICATION WITH SAUDI FDA FOR QRX003 IN NETHERTON SYNDROME  SUBMITTED APPLICATION TO JAPANESE MHLW FOR ORPHAN DRUG DESIGNATION (ODD) FOR QRX003; MHLW CONFIRMED QRX003 QUALIFIES FOR BOTH ORPHAN DRUG DESIGNATION AND FAST TRACK REVIEW  U.S. FDA GRANTED FAST TRACK DESIGNATION TO QRX003 LOTION (4%) FOR THE TREATMENT OF NETHERTON SYNDROME, COMPLEMENTING PREVIOUSLY GRANTED ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS  CONSTRUCTIVE TYPE C MEETING WITH FDA: SINGLE PHASE 3 STUDY MAY BE SUFFICIENT TO SUPPORT U.S. MARKETING APPROVAL; FDA OPEN TO TRIAL DESIGN WITHOUT TRADITIONAL VEHICLE OR PLACEBO CONTROL  RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM EXTENDED BY CONGRESS THROUGH SEPTEMBER 30, 2029  ON TRACK TO COMPLETE PHASE 3 PATIENT RECRUITMENT BY END OF 2026, WITH POTENTIAL NDA FILING IN 2027 FOR QRX003 AS THE FIRST APPROVED TREATMENT FOR NETHERTON SYNDROME ASHBURN, VA., MAY 07, 2026 (GLOBE NEWSWIRE) -- QUOIN PHARMACEUTICALS LTD.

Quoin Pharmaceuticals, Ltd.

QNRX

Price

Financial Reports

No items found.

Press Releases

Quoin Pharmaceuticals, Ltd.

QNRX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

QNRX